Family · Pharmaceutical analytical standards
Milrinone
A phosphodiesterase 3 inhibitor that strengthens the heart's contraction and widens the blood vessels, approved in the United States in 1987: it is given intravenously for short-term treatment of heart failure and after heart surgery. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?It works without going through beta-adrenergic receptors, which tend to decrease in the failing heart: it raises cAMP in heart cells simply by slowing its breakdown.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
